Mylan Launches Generic Omeprazole; Takes Risk For Purple Gold
Executive Summary
Mylan's decision to launch the second generic version of AstraZeneca's Prilosec (omeprazole) could inject a new level of price competition into the proton pump inhibitor category
You may also be interested in...
Schwarz and Mylan settle omeprazole dispute
Schwarz' Kremers Urban Development Company will pay Mylan and its development partner, Spain-based Esteve Quimica, $50 mil. under June 25 agreement to settle lawsuits related to generic omeprazole (1"The Pink Sheet" Aug. 11, 2003, p. 11). Mylan will receive $37.5 mil and Esteve Quimica will receive $12.5 mil...
Schwarz and Mylan settle omeprazole dispute
Schwarz' Kremers Urban Development Company will pay Mylan and its development partner, Spain-based Esteve Quimica, $50 mil. under June 25 agreement to settle lawsuits related to generic omeprazole (1"The Pink Sheet" Aug. 11, 2003, p. 11). Mylan will receive $37.5 mil and Esteve Quimica will receive $12.5 mil...
Mylan sues over Prilosec OTC
Procter & Gamble's Prilosec OTC is falsely represented as identical to AstraZeneca's prescription version of the proton pump inhibitor, Mylan alleges in a Manhattan federal court lawsuit. Mylan also recently submitted a study to FDA that the company asserts demonstrates OTC omeprazole is not bioequivalent to Prilosec. P&G maintains the Rx and OTC 20 mg formulations are the same. Mylan alleges P&G's claims will divert sales from its own generic omeprazole, which launched "at risk" in August (1"The Pink Sheet" Aug. 11, 2003, p. 11)...